LifeVantage Reports Steep Q3 Revenue & Profit Decline, Active Accounts Drop 22%, Cash Drains

summarizeSummary

LifeVantage Corp reported significantly weaker Q3 fiscal 2026 results, with revenue down 25% and net income plummeting over 60%, alongside a substantial 22% decrease in active customer accounts.

check_boxKey Events

• Significant Revenue Decline

  Q3 fiscal 2026 net revenue decreased by 25.2% to $43.7 million, and year-to-date revenue fell by 19.1% to $140.2 million, primarily due to reduced sales of the MindBody GLP-1 System. This follows the significantly weaker-than-anticipated Q3 fiscal 2026 financial results reported in a concurrent 8-K filing.

• Sharp Profitability Drop

  Q3 net income decreased by 60.7% to $1.4 million, with basic EPS falling to $0.11 from $0.28 in the prior year, reflecting severe operational challenges.

• Active Accounts Plummet

  Total active accounts (independent consultants and customers) decreased by 22.1% year-over-year to 109,000, indicating a significant contraction in their direct selling network.

• Cash Position Weakens

  Cash and cash equivalents declined by 38.2% to $12.5 million since June 30, 2025, with net cash provided by operating activities nearly halved to $5.5 million for the nine-month period.

auto_awesomeAnalysis

LifeVantage Corp's third-quarter results reveal a substantial deterioration in its core business, marked by significant declines in revenue, net income, and active customer base. The sharp drop in active accounts is particularly concerning for a direct selling model, suggesting fundamental challenges in customer acquisition and retention. The increase in inventory obsolescence and the downward adjustment of the LoveBiome acquisition earnout further underscore operational difficulties and underperformance. While the new $60 million stock repurchase program offers a positive signal of management's confidence or an attempt to support the stock, the magnitude of the financial and operational setbacks presented in this report is overwhelmingly negative. The $75 million shelf registration provides capital access but also introduces the risk of significant future dilution if the company needs to raise funds at depressed valuations. Investors should monitor the company's ability to stabilize its active account base and improve sales performance, especially for key product lines like MindBody GLP-1 System, and assess the impact of any future capital raises.